Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP VEN: Venetoclax and Azacitidine Discontinuation in AML
NCT06557421Phase 2Recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- Feb 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Primary endpoint: Disease-Free Survival at 24 months. Started Feb 2026; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06557421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557421.